Spectrum Pharmaceuticals begins Phase 2 clinical program for SPI-2012

[News]

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the Company has initiated a Phase 2 clinical program for SPI-2012 (also referred to as "LAPS-GCSF"), a drug candidate for the treatment of chemotherapy-induced neutropenia that utilizes partner Hanmi Pharmaceutical Company's proprietary LAPSCOVERY™ Technology.

More... (http://www.news-medical.net/news/20130408/Spectrum-Pharmaceuticals-begins-Phase-2-clinical-program-for-SPI-2012.aspx)